The most common adverse events occurring more frequently in the evolocumab-treated patients than in the placebo groups were nasopharyngitis ( in @ patients -LSB- @ % -RSB- vs five -LSB- @ % -RSB- in the placebo group ) and muscle-related adverse events ( ten patients -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .